A top-5 pharmaceutical company needed to prepare decision-makers for the patient and health system impact of disease-modifying therapies and diagnostic biomarkers for Alzheimer’s disease.
A large biotech firm needed support in developing an evidence-based policy narrative in preparation for the launch of a CAR T-cell therapy for a rare form of cancer.
The global headquarters of a top-5 pharmaceutical company needed to develop a global policy strategy to support the launch of a new treatment for influenza.
A global biopharmaceutical company recognized the need to work in partnership with healthcare systems in order to realize the vital, long-term potential of a personalized approach to healthcare.
A multinational pharmaceutical company sought support to engage with haemophilia A individuals and caregivers to gather firsthand perspectives on the impact of current and value of future therapies.